Skip to main content
SpringerLink
Log in

Recurrent ipsilateral pheochromocytoma in carriers of RET p.Cys634 missense mutations

  • Original Article
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Purpose

The objective of this study was to provide RET genotype-specific data on recurrent ipsilateral pheochromocytoma in multiple endocrine neoplasia type 2A (MEN2A), which are sparse.

Methods

Kaplan-Meier analyses were performed to determine the risk of recurrent ipsilateral adrenalectomy after subtotal and total adrenalectomy in 221 carriers of RET p.Cys634 missense mutations.

Results

Altogether, pheochromocytoma emerged in 112 of 442 adrenals at risk, for which 63 adrenals underwent total adrenalectomy and 49 adrenals subtotal adrenalectomy. After a mean (median) of 99 (132.9) months, 10 recurrent ipsilateral pheochromocytomas arose in 10 (20.4%) of 49 adrenal remnants. Seven of these 10 adrenal remnants were subjected to total adrenalectomy and 3 to another subtotal adrenalectomy. After 23 and 250 (mean/median 136.5) more months, 2 of the 3 remaining adrenal remnants gave rise to 2 further recurrent ipsilateral pheochromocytomas, which were removed by total adrenalectomy. When the rare publications in which carriers of RET p.Cys634 mutations made up 81–84% of MEN2A patients were combined with the present RET p.Cys634-specific series, the risk of recurrent ipsilateral pheochromocytoma was 6.7% (25 recurrent ipsilateral pheochromocytomas in 375 adrenal remnants), with a mean time interval of 146 months after initial subtotal adrenalectomy.

Conclusion

Subtotal adrenalectomy is a viable treatment option for many carriers of RET p.Cys634 mutations who develop an initial pheochromocytoma. Although the adrenal remnant may give rise to recurrent ipsilateral pheochromocytoma after 8–11 years in up to 20% of patients, it is manageable very well in experienced hands, buying the patient valuable time off steroids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. S.A. Wells Jr, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid 25, 567–610 (2015)

    Article  Google Scholar 

  2. A. Machens, H. Dralle, Long-term outcome after DNA-based prophylactic neck surgery in children at risk of hereditary medullary thyroid cancer. Best Pract. Res. Clin. Endocrinol. Metab. 33, 101274 (2019)

    Article  Google Scholar 

  3. R.M.B. Maciel, A.L. Maia, Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: A comprehensive review. Eur. J. Endocrinol. 186, R15–R30 (2022)

    Article  Google Scholar 

  4. A. Machens, P. Niccoli-Sire, J. Hoegel, K. Frank-Raue, T.J. van Vroonhoven, H.D. Roeher, R.A. Wahl, P. Lamesch, F. Raue, B. Conte-Devolx, H. Dralle, European Multiple Endocrine Neoplasia (EUROMEN) Study Group. Early malignant progression of hereditary medullary thyroid cancer. N. Engl. J. Med. 349, 1517–1525 (2003)

    Article  CAS  Google Scholar 

  5. A. Machens, K. Lorenz, F. Weber, H. Dralle, Genotype-specific progression of hereditary medullary thyroid cancer. Hum. Mutat. 39, 860–869 (2018)

    Article  CAS  Google Scholar 

  6. A. Machens, K. Lorenz, H. Dralle, Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: Need for age-adjusted biochemical screening. J. Clin. Endocrinol. Metab. 98, E336–E345 (2013)

    Article  CAS  Google Scholar 

  7. L. Mucha, G. Leidig-Bruckner, K. Frank-Raue, T. Bruckner, M. Kroiss, F. Raue, German study group for rare thyroid cancer. Phaeochromocytoma in multiple endocrine neoplasia type 2: RET codon-specific penetrance and changes in management during the last four decades. Clin. Endocrinol. 87, 320–326 (2017)

    Article  CAS  Google Scholar 

  8. I. Schuffenecker, M. Virally-Monod, R. Brohet, D. Goldgar, B. Conte-Devolx, L. Leclerc, O. Chabre, A. Boneu, J. Caron, C. Houdent, E. Modigliani, V. Rohmer, M. Schlumberger, C. Eng, P.J. Guillausseau, G.M. Lenoir, Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe d’Etude des Tumeurs à Calcitonine. J. Clin. Endocrinol. Metab. 83, 487–491 (1998)

  9. A. Machens, M. Elwerr, K. Lorenz, F. Weber, H. Dralle. Long-term outcome of prophylactic thyroidectomy in children carrying RET germline mutations. Br. J. Surg. 105, e150–e157 (2018)

    Article  CAS  Google Scholar 

  10. G. Eisenhofer, K. Pacak, T.T. Huynh, N. Qin, G. Bratslavsky, W.M. Linehan, M. Mannelli, P. Friberg, S.K. Grebe, H.J. Timmers, S.R. Bornstein, J.W. Lenders, Catecholamine metabolomic and secretory phenotypes in phaeochromocytoma. Endocr. Relat. Cancer 18, 97–111 (2010)

    Article  Google Scholar 

  11. M.L. Li, P.A. Fitzgerald, D.C. Price, J.A. Norton, Iatrogenic pheochromocytomatosis: A previously unreported result of laparoscopic adrenalectomy. Surgery 130, 1072–1077 (2001)

    Article  CAS  Google Scholar 

  12. H. Dralle, G.F. Scheumann, J. Kotzerke, E.G. Brabant, Surgical management of MEN 2. Recent Results Cancer Res. 125, 167–195 (1992)

    Article  CAS  Google Scholar 

  13. M. Brauckhoff, O. Gimm, P.N. Thanh, A. Bär, J. Ukkat, K. Brauckhoff, T. Bönsch, H. Dralle, Critical size of residual adrenal tissue and recovery from impaired early postoperative adrenocortical function after subtotal bilateral adrenalectomy. Surgery 134, 1020–1027 (2003)

    Article  Google Scholar 

  14. L. Yip, J.E. Lee, S.E. Shapiro, S.G. Waguespack, S.I. Sherman, A.O. Hoff, R.F. Gagel, J.F. Arens, D.B. Evans, Surgical management of hereditary pheochromocytoma. J. Am. Coll. Surg. 198, 525–534 (2004)

    Article  Google Scholar 

  15. E.G. Grubbs, T.A. Rich, C. Ng, P.R. Bhosale, C. Jimenez, D.B. Evans, J.E. Lee, N.D. Perrier, Long-term outcomes of surgical treatment for hereditary pheochromocytoma. J. Am. Coll. Surg. 216, 280–289 (2013)

    Article  Google Scholar 

  16. R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng, Pathology and genetics of tumours of endocrine organs; In: WHO classification of tumours of endocrine organs. In: Lloyd, R.V., ed. WHO classification of tumours of endocrine organs (3rd edn). International Agency for Research on Cancer; 2017

  17. E.L. Kaplan, P. Meier, Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457–481 (1958)

    Article  Google Scholar 

  18. R. Peto, M.C. Pike, P. Armitage, N.E. Breslow, D.R. Cox, S.V. Howard, N. Mantel, K. McPherson, J. Peto, P.G. Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II analysis and examples. Br. J. Cancer 35, 1–39 (1977)

    Article  CAS  Google Scholar 

  19. F. Castinetti, X.P. Qi, M.K. Walz, A.L. Maia, G. Sansó, M. Peczkowska, K. Hasse-Lazar, T.P. Links, S. Dvorakova, R.A. Toledo, C. Mian, M.J. Bugalho, N. Wohllk, O. Kollyukh, L. Canu, P. Loli, S.R. Bergmann, J. Biarnes Costa, O. Makay, A. Patocs, M. Pfeifer, N.S. Shah, T. Cuny, M. Brauckhoff, B. Bausch, E. von Dobschuetz, C. Letizia, M. Barczynski, M.K. Alevizaki, M. Czetwertynska, M.U. Ugurlu, G. Valk, J.T. Plukker, P. Sartorato, D.R. Siqueira, M. Barontini, M. Szperl, B. Jarzab, H.H. Verbeek, T. Zelinka, P. Vlcek, S.P. Toledo, F.L. Coutinho, M. Mannelli, M. Recasens, L. Demarquet, L. Petramala, S. Yaremchuk, D. Zabolotnyi, F. Schiavi, G. Opocher, K. Racz, A. Januszewicz, G. Weryha, J.F. Henry, T. Brue, B. Conte-Devolx, C. Eng, H.P. Neumann, Outcomes of adrenal-sparing surgery or total adrenalectomy in phaeochromocytoma associated with multiple endocrine neoplasia type 2: an international retrospective population-based study. Lancet Oncol. 15, 648–655 (2014)

    Article  Google Scholar 

  20. H.P.H. Neumann, U. Tsoy, I. Bancos, V. Amodru, M.K. Walz, A. Tirosh, R.J. Kaur, T. McKenzie, X. Qi, T. Bandgar, R. Petrov, M.Y. Yukina, A. Roslyakova, A.N.A. van der Horst-Schrivers, A.M.A. Berends, A.O. Hoff, L.A. Castroneves, A.M. Ferrara, S. Rizzati, C. Mian, S. Dvorakova, K. Hasse-Lazar, A. Kvachenyuk, M. Peczkowska, P. Loli, F. Erenler, T. Krauss, M.Q. Almeida, L. Liu, F. Zhu, M. Recasens, N. Wohllk, E.P.M. Corssmit, Z. Shafigullina, J. Calissendorff, S. Grozinsky-Glasberg, T. Kunavisarut, C. Schalin-Jäntti, F. Castinetti, P. Vlcek, D. Beltsevich, V.I. Egorov, F. Schiavi, T.P. Links, R.M. Lechan, B. Bausch, W.F. Young Jr, C. Eng; International Bilateral-Pheochromocytoma-Registry Group, Comparison of pheochromocytoma-specific morbidity and mortality among adults with bilateral pheochromocytomas undergoing total adrenalectomy vs cortical-sparing adrenalectomy. JAMA Netw. Open 2, e198898 (2019)

    Article  Google Scholar 

  21. C. Eng, D. Clayton, I. Schuffenecker, G. Lenoir, G. Cote, R.F. Gagel, H.K. van Amstel, C.J. Lips, I. Nishisho, S.I. Takai, D.J. Marsh, B.G. Robinson, K. Frank-Raue, F. Raue, F. Xue, W.W. Noll, C. Romei, F. Pacini, M. Fink, B. Niederle, J. Zedenius, M. Nordenskjöld, P. Komminoth, G.N. Hendy, H. Gharib, S.N. Thibodeau, A. Lacroix, A. Frilling, B.A.J. Ponder, L.M. Mulligan, The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA 276, 1575–1579 (1996)

    Article  CAS  Google Scholar 

  22. J.M. Rodriguez, M. Balsalobre, J.L. Ponce, A. Ríos, N.M. Torregrosa, J. Tebar, P. Parrilla, Pheochromocytoma in MEN 2A syndrome. Study of 54 patients. World J. Surg. 32, 2520–2526 (2008)

  23. A. Machens, H. Dralle, Variability in penetrance of multiple endocrine neoplasia 2A with amino acid substitutions in RET codon 634. Clin. Endocrinol. 84, 210–215 (2016)

    Article  CAS  Google Scholar 

  24. S.J. Diaz-Cano, M. de Miguel, A. Blanes, R. Tashjian, H. Galera, H.J. Wolfe, Clonal patterns in phaeochromocytomas and MEN-2A adrenal medullary hyperplasias: histological and kinetic correlates. J. Pathol. 192, 221–228 (2000)

    Article  CAS  Google Scholar 

  25. E. Korpershoek, B.J. Petri, E. Post, C.H. van Eijck, R.A. Oldenburg, E.J. Belt, W.W. de Herder, R.R. de Krijger, W.N. Dinjens, Adrenal medullary hyperplasia is a precursor lesion for pheochromocytoma in MEN2 syndrome. Neoplasia 16, 868–873 (2014)

  26. M. Brauckhoff, K. Stock, S. Stock, K. Lorenz, C. Sekulla, K. Brauckhoff, P.N. Thanh, O. Gimm, R.P. Spielmann, H. Dralle, Limitations of intraoperative adrenal remnant volume measurement in patients undergoing subtotal adrenalectomy. World J. Surg. 32, 863–872 (2008)

Download references

Author information

Authors and Affiliations

  1. Medical Faculty, Department of Visceral, Vascular and Endocrine Surgery, Martin Luther University Halle-Wittenberg, Ernst-Grube-Str. 40, D-06097, Halle (Saale), Germany

    Andreas Machens, Kerstin Lorenz & Henning Dralle

  2. Department of General, Visceral and Transplantation Surgery, Section of Endocrine Surgery, University of Duisburg-Essen, D-45122, Essen, Germany

    Frank Weber & Henning Dralle

Authors
  1. Andreas Machens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kerstin Lorenz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Henning Dralle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andreas Machens.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Ethics approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from each patient and/or legal guardian as applicable before each RET gene test and each operation, all of which represented standard of care.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Machens, A., Lorenz, K., Weber, F. et al. Recurrent ipsilateral pheochromocytoma in carriers of RET p.Cys634 missense mutations. Endocrine 77, 160–167 (2022). https://doi.org/10.1007/s12020-022-03073-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-022-03073-0

Keywords

Search

Navigation